Li, F., & Dong, X. (2021). Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial. Wiley.
Chicago Style (17th ed.) CitationLi, Fengtan, and Xifeng Dong. Pembrolizumab Provides Long‐term Survival Benefits in Advanced Non‐small Cell Lung Cancer: The 5‐year Outcomes of the KEYNOTE‐024 Trial. Wiley, 2021.
MLA (8th ed.) CitationLi, Fengtan, and Xifeng Dong. Pembrolizumab Provides Long‐term Survival Benefits in Advanced Non‐small Cell Lung Cancer: The 5‐year Outcomes of the KEYNOTE‐024 Trial. Wiley, 2021.
Warning: These citations may not always be 100% accurate.